NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/8/2026

1. USO
2. SPY
3. TMUS
4. AMZN
5. RKLB
6. FLUT
7. PENG
8. KRUS
9. MTZ
10. NDAQ

Go back to NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
(NASDAQ: CELU) Delayed: 0.74 +0.01 (1.37%)
Previous Close $0.73    52 Week High $ 
Open $0.74    52 Week Low $ 
Day High $0.74    P/E N/A 
Day Low $0.73    EPS $ 
Volume 4,176